Table 5.

Concomitant treatment of LS174T cells with BR+NAC

LS174T Combo	Cis			PTX
	5	10	20	10	50	100
BR 10 + NAC 5	< 0.0001	< 0.0001	< 0.0001	0.0113	n	n
BR 10 + NAC 10	< 0.0001	0.0028	n	< 0.0001	< 0.0001	< 0.0001
BR 10 + NAC 20	< 0.0001	< 0.0001	n	< 0.0001	< 0.0001	< 0.0001
BR 20 + NAC 5	n	0.0495	0.6338	< 0.0001	< 0.0001	< 0.0001
BR 20 + NAC 10	0.0002	< 0.0001	n	< 0.0001	< 0.0001	< 0.0001
BR 20 + NAC 20	< 0.0001	0.0003	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BR 30 + NAC 5	0.0143	0.0032	0.0003	< 0.0001	< 0.0001	< 0.0001
BR 30 + NAC 10	n	< 0.0001	n	< 0.0001	< 0.0001	< 0.0001
BR 30 + NAC 20	< 0.0001	< 0.0001	0.3427	< 0.0001	< 0.0001	< 0.0001
	5FU			VCR
	10	50	100	10	50	100
BR 10 + NAC 5	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.0004	0.0008
BR 10 + NAC 10	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.0002	< 0.0001
BR 10 + NAC 20	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BR 20 + NAC 5	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BR 20 + NAC 10	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BR 20 + NAC 20	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BR 30 + NAC 5	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BR 30 + NAC 10	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BR 30 + NAC 20	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001

Cis: cisplatin; 5FU: 5-fluorouracil; PTX: paclitaxel; VCR: vincristine; n: not significant. Italic text or digits highlight concentrations at which BR/NAC enhanced theeffect of chemotherapy. Significant results (p < 0.05) are shown in bold.